Protocol Ledger

NCT03368170 · Phase II · COMPLETED

Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia

Interventional Phase II clinical trial protocol NCT03368170 sponsored by Integrative Research Laboratories in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-04-12 Enrollment: 75 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03368170
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)75 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03368170
Protocol FieldVerified Registry Value
NCT IdentifierNCT03368170
Consolidated Lead SponsorIntegrative Research Laboratories
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment75 participants (ACTUAL)
Registered Start Date2018-04-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03368170
Hospital Research SiteLocationSite Profile
Sahlgrenska University hospitalGothenburg, SwedenOpen Hospital Dossier ->
Karolinska University HospitalStockholm, SwedenOpen Hospital Dossier ->
John Radcliffe HospitalOxford, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI